Lung Cancer Clinical Trials in Phoenix

Showing 241-260 of 454 trials

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

NCT03409458

This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study of PT-112 in combination with the anti-PD-L1 antibody, avelumab, in selected advanced solid tumors. The study is to be conducted in two parts: the Dose Escalation Phase of PT-112 within the combination and the Dose Confirmation Phase in patients with non-small cell lung cancer who will be treated at the RP2D.

Non-Small Cell Lung Cancer (NSCLC)

Promontory Therapeutics Inc.68 participantsStarted Apr 2018

Phoenix, Arizona, United States • Aurora, Colorado, United States • Jacksonville, Florida, United States +3 more locations

COMPLETEDPhase 1/2< 1 mile

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

NCT02988817

The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors

Ovarian CancerCervical CancerEndometrial Cancer+5 more

Genmab306 participantsStarted Nov 2016

Phoenix, Arizona, United States • Aurora, Colorado, United States • New Haven, Connecticut, United States +38 more locations

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Lung Cancer Trials in Other Cities

Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Survival Prolongation by Rationale Innovative Genomics

Study of the CD40 Agonistic Monoclonal Antibody APX005M

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Palliative Care Interventions for Outpatients Newly Diagnosed With Lung Cancer: Phase II

International Lung Screen Trial (ILST)

Other Conditions in Phoenix